Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 724-733
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.724
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.724
Curative | Relapse | Total | P value | |
Patients, n | 188 (74.3) | 65 (25.7) | 253 | |
Age, mean ± SD (yr) | 58.51 ± 10.53 | 58.23 ± 8.33 | 58.43 ± 9.99 | 0.83 |
Sex, n (%) | 0.24 | |||
Male | 128 (68.1) | 39 (60.0) | 167 (66.0) | |
Female | 60 (31.9) | 26 (40.0) | 86 (34.0) | |
Location of lesions, n (%) | 0.08 | |||
Gastric fundus - cardia area | 5 (2.7) | 1 (1.5) | 6 (2.4) | |
Gastric body | 19 (10.1) | 5 (7.7) | 24 (9.5) | |
Angle of stomach | 32 (17.0) | 21 (32.3) | 53 (20.9) | |
Antrum of the stomach - pylorus area | 132 (70.2) | 38 (58.5) | 170 (67.2) | |
Ulceration | 0 | 0 | 0 | |
Helicobacter pylori infection, n (%) | < 0.001 | |||
Yes | 8 (4.3) | 37 (56.9) | 45 (17.8) | |
No | 180 (95.7) | 28 (43.1) | 208 (82.2) | |
Atrophy, n (%) | < 0.001 | |||
Yes | 49 (26.1) | 39 (60.0) | 88 (34.8) | |
No | 139 (73.9) | 26 (40.0) | 165 (65.2) | |
A course of disease, n (%) | < 0.001 | |||
< 1 yr | 138 (73.4) | 14 (21.5) | 152 (60.1) | |
> 1 yr | 50 (26.6) | 51 (78.5) | 101 (39.9) |
Follow-up period | n | Curative, n (%) | Relapse, n (%) | Recurrence, n (%) | Progression, n (%) |
3 mo | 253 | 236 (93.3) | 17 (6.7) | 18 (7.1) | 2 (0.8) |
6 mo | 208 | 193 (92.8) | 15 (7.2) | 11 (5.3) | 0 |
1 yr | 141 | 129 (91.5) | 12 (8.5) | 14 (9.9) | 0 |
2 yr | 93 | 84 (90.3) | 9 (9.7) | 8 (8.6) | 1 (1.1) |
3 yr | 61 | 54 (88.5) | 7 (11.5) | 6 (9.8) | 2 (3.3) |
4 yr | 28 | 24 (85.7) | 4 (14.3) | 4 (14.3) | 0 |
5 yr | 6 | 5 (83.3) | 1 (16.7) | 1 (16.7) | 0 |
Univariate | Multivariate | |||
P value | HR (95%CI) | P value | HR (95%CI) | |
Sex | 0.43 | 0.817 (0.494-1.351) | ||
Age | 0.89 | 0.998 (0.974-1.023) | ||
Location | 0.29 | |||
Gastric body | 0.674 (0.092-4.919) | |||
Angle of stomach | 1.242 (0.487-3.167) | |||
Antrum of the stomach - pylorus area | 1.644 (0.963-2.808) | |||
H. pylori infection | < 0.001 | 6.053 (3.679-9.957) | < 0.001 | 2.662 (1.225-5.788) |
Atrophy | < 0.001 | 2.136 (1.024-4.453) | 0.597 | 1.170 (0.653-2.097) |
Course of disease | < 0.001 | 5.482 (3.029-9.919) | 0.013 | 2.662 (1.225-5.788) |
- Citation: Wang NJ, Chai NL, Tang XW, Li LS, Zhang WG, Linghu EQ. Clinical efficacy and prognostic risk factors of endoscopic radiofrequency ablation for gastric low-grade intraepithelial neoplasia. World J Gastrointest Oncol 2022; 14(3): 724-733
- URL: https://www.wjgnet.com/1948-5204/full/v14/i3/724.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i3.724